Uric acid, hypertension, and cardiovascular and renal complications.
Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease. A substantial proportion of epidemiological studies are compatible with the hypothesis that hyperuricemia may be noxious to the CV system and the kidney as well. However, there are still no well-powered trials testing whether uric acid-lowering interventions may reduce BP or attenuate the risk for adverse CV and renal outcomes. Evidence still remains largely insufficient to recommend changes in the current policy of not prescribing uric acid-lowering drugs to individuals with asymptomatic hyperuricemia.
CNR National Research Council (Italy) Clinical Epidemiology and Physiopathology of Renal Disease and Hypertension Unit and Nephrology, Hypertension and Renal Transplantation unit, Ospedali Riuniti, Reggio Calabria, 89124, Italy, carmine.zoccali@tin.it.
Carmine
C
Zoccali
Francesca
F
Mallamaci
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000150:complications*; D033461:Hyperuricemia / Q000150:complications / Q000503:physiopathology*; D007674:Kidney Diseases / Q000209:etiology*; D014527:Uric Acid / Q000378:metabolism*; D014652:Vascular Diseases / Q000150:complications*
D014527:Uric Acid